Ping An Securities Research Report pointed out that Puri Ophthalmology's Q3 performance improved at an accelerated pace. Net profit to mother for the first three quarters of 2026 was 151 million yuan, up 823.97% year on year, and net profit from Q3 was 63 million yuan, up 3643.42% year on year. Slow down the pace of epitaxial extension and focus on improving the operational efficiency of existing hospitals. In the first half of 2026, the company took the initiative to slow down the pace of epitaxial expansion, and its strategic focus completely shifted to focus on endogenous growth and operational efficiency improvement. At the same time, it continued to deepen and improve the regional integration layout, and implemented a clustered development strategy in key regions. As of the 26th mid-year report, the company operates 41 ophthalmology hospitals and 3 outpatient clinics in 26 cities across the country. The company focuses on talent development and collaborative development of medical education and research. Based on the company's profit side recovery in 2026 and seasonal factors affecting the company's Q4 operations, the profit forecast for 2026-2028 is expected to be 1.35, 2.05, and 265 million yuan. The company's operating performance continues to improve, profit margins are expected to continue to improve, and the “recommended” rating is maintained.

Ping An Securities Research Report pointed out that Puri Ophthalmology's Q3 performance improved at an accelerated pace. Net profit to mother for the first three quarters of 2026 was 151 million yuan, up 823.97% year on year, and net profit from Q3 was 63 million yuan, up 3643.42% year on year. Slow down the pace of epitaxial extension and focus on improving the operational efficiency of existing hospitals. In the first half of 2026, the company took the initiative to slow down the pace of epitaxial expansion, and its strategic focus completely shifted to focus on endogenous growth and operational efficiency improvement. At the same time, it continued to deepen and improve the regional integration layout, and implemented a clustered development strategy in key regions. As of the 26th mid-year report, the company operates 41 ophthalmology hospitals and 3 outpatient clinics in 26 cities across the country. The company focuses on talent development and collaborative development of medical education and research. Based on the company's profit side recovery in 2026 and seasonal factors affecting the company's Q4 operations, the profit forecast for 2026-2028 is expected to be 1.35, 2.05, and 265 million yuan. The company's operating performance continues to improve, profit margins are expected to continue to improve, and the “recommended” rating is maintained.